A Meta-Analysis of Randomized Controlled Trials Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Alone in HER-2-Positive Advanced Breast Cancer

被引：6
|
作者：
Liao, Cun [1 ]
Yin, Fang [1 ]
Huang, Ping [1 ]
Cao, Yunfei [1 ]
Gao, Feng [1 ]
机构：
[1] Guangxi Med Univ, Affiliated Hosp 1, Dept Colorectal & Anal Surg, Nanning, Guangxi, Peoples R China
来源：
BREAST JOURNAL | 2011年 / 17卷 / 01期
关键词：
PHASE-II TRIAL; PACLITAXEL; THERAPY;
D O I：
10.1111/j.1524-4741.2010.01034.x
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：109 / 111
页数：3
相关论文
共 50 条
  • [41] Survival benefit of pure dose-dense chemotherapy in breast cancer: a meta-analysis of randomized controlled trials
    Zhou, Wenqi
    Chen, Shizhe
    Xu, Faliang
    Zeng, Xiaohua
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2018, 16
  • [42] Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancer
    Belfiglio, Maurizio
    Fanizza, Caterina
    Tinari, Nicola
    Ficorella, Corrado
    Iacobelli, Stefano
    Natoli, Clara
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2012, 138 (02) : 221 - 229
  • [43] Complete response after "neoadjuvant" pertuzumab plus trastuzumab plus docetaxel chemotherapy in Her2-positive breast cancer
    Lai-Tiong, F.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2018, 39 (05) : 836 - 837
  • [44] Efficacy and Safety of Bevacizumab Combined with Chemotherapy for Managing Metastatic Breast Cancer: A Meta-Analysis of Randomized Controlled Trials
    Li, Qin
    Yan, Han
    Zhao, Pengfei
    Yang, Yifan
    Cao, Bangwei
    SCIENTIFIC REPORTS, 2015, 5
  • [45] Adjuvant trastuzumab chemotherapy in early breast cancer: meta-analysis of randomised trials and cost-effectiveness analysis
    Nhut, Doan Tan
    Jan, Barendregt
    SWISS MEDICAL WEEKLY, 2019, 149
  • [46] Beyond Trastuzumab: Small Molecule Tyrosine Kinase Inhibitors in HER-2-Positive Breast Cancer
    Roy, Vivek
    Perez, Edith A.
    ONCOLOGIST, 2009, 14 (11) : 1061 - 1069
  • [47] Lapatinib combined with neoadjuvant paclitaxel-trastuzumab-based chemotherapy in patients with human epidermal growth factor receptor. 2-positive breast cancer: A meta-analysis of randomized controlled trials
    Sun, Jinzhong
    Chen, Chuang
    Yao, Xiaoli
    Sun, Shengrong
    ONCOLOGY LETTERS, 2015, 9 (03) : 1351 - 1358
  • [48] Cost-Effectiveness Analysis of Lapatinib in HER-2-Positive Advanced Breast Cancer
    Le, Quang A.
    Hay, Joel W.
    CANCER, 2009, 115 (03) : 489 - 498
  • [49] Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study)
    Hasegawa, Yoshie
    Tanino, Hirokazu
    Horiguchi, Jun
    Miura, Daishu
    Ishikawa, Takashi
    Hayashi, Mitsuhiro
    Takao, Shintaro
    Kim, Seung Jin
    Yamagami, Kazuhiko
    Miyashita, Masaru
    Konishi, Muneharu
    Shigeoka, Yasushi
    Suzuki, Masato
    Taguchi, Tetsuya
    Kubota, Tomoyuki
    Akazawa, Kouhei
    Kohno, Norio
    PLOS ONE, 2015, 10 (12):
  • [50] Cost-effectiveness analysis of trastuzumab monotherapy versus adjuvant chemotherapy plus trastuzumab in elderly patients with HER2-positive early breast cancer
    Konishi, Takaaki
    Fujiogi, Michimasa
    Michihata, Nobuaki
    Ohbe, Hiroyuki
    Matsui, Hiroki
    Fushimi, Kiyohide
    Tanabe, Masahiko
    Seto, Yasuyuki
    Yasunaga, Hideo
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (10) : 1115 - 1123
12345